Stryker Corporation

Stryker Corporation Earnings Recaps

SYK Health Care 3 recaps
Q1 2026 May 4, 2026

Stryker's shares declined 6.5% following earnings as the market reacted negatively to the significant impact of a late-quarter cyber incident, which disrupted revenue recognition and led to meaningful margin pressure despite stable underlying demand.

Key takeaways
  • Organic sales growth moderated to 2.4%, reflecting constrained revenue due to cyber-related operational disruptions late in the quarter.
  • Adjusted EPS declined 8.5% year-over-year to $2.60, weighed down by lost manufacturing absorption, tariffs, and higher interest expense.
  • The cyber incident caused shipment delays and revenue timing distortions, prompting management to withhold normal segment-level details this quarter.
  • Robust procedural demand and elevated capital order book signals underlying market health despite first-quarter headwinds.
  • The company reaffirmed full-year guidance, anticipating normalization as recovery efforts conclude.
Full recap
Q3 2025 Nov 1, 2025

Stryker reported a strong third quarter with 9.5% organic sales growth and 11.1% adjusted EPS growth, driven by broad demand across its business segments despite tariff pressures.

Key takeaways
  • U.S. organic sales grew by 10.6%, led by double-digit increases in Vascular, Trauma, and Neuro Cranial categories.
  • Two strategic acquisitions were completed, enhancing product offerings in wound treatment and patient care.
  • Mako robot installations hit a record high, reinforcing Stryker's leadership in the orthopedic market.
  • The company increased its full-year outlook, anticipating continued momentum in sales and operating margin improvement.
  • The integration of Inari is progressing well, contributing to robust pro forma growth.
Full recap
Q2 2025 Aug 1, 2025

Stryker delivered robust second quarter results, achieving a 10.2% organic sales growth and an 11.4% increase in adjusted EPS, driven by strong performance across its MedSurg, Neurotechnology, and orthopedic segments.

Key takeaways
  • U.S. organic sales growth was particularly strong at 11.5%, with notable contributions from Endoscopy and neurocranial businesses.
  • International sales grew 6.5% despite supply chain challenges, with emerging markets showing promising demand.
  • Stryker is on track to boost its full-year 2025 outlook and anticipates an additional 100 basis points of operating margin expansion.
  • The integration of recent acquisitions is progressing, with expectations of double-digit pro forma growth for 2025.
  • An impressive milestone of 2 million robotic procedures performed with Mako reinforces Stryker’s leadership in orthopedic robotics.
Full recap